Tanaya Shree, MD, Stanford University Medical Center, California, CA, discusses the interim clinical and correlative results of the Phase I/II trial of the CpG TLR9 agonist SD-101, ibrutinib and radiation therapy in relapsed/refractory low-grade follicular lymphoma (NCT02927964). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
